Form 8-K - Current report:
SEC Accession No. 0001193125-25-021771
Filing Date
2025-02-06
Accepted
2025-02-06 16:05:14
Documents
14
Period of Report
2025-01-31
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d875218d8k.htm   iXBRL 8-K 34700
2 EX-10.1 d875218dex101.htm EX-10.1 9646
  Complete submission text file 0001193125-25-021771.txt   172388

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vinc-20250131.xsd EX-101.SCH 2838
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE vinc-20250131_lab.xml EX-101.LAB 17978
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vinc-20250131_pre.xml EX-101.PRE 11250
16 EXTRACTED XBRL INSTANCE DOCUMENT d875218d8k_htm.xml XML 3630
Mailing Address 260 SHERIDAN AVENUE SUITE 400 PALO ALTO CA 94306
Business Address 260 SHERIDAN AVENUE SUITE 400 PALO ALTO CA 94306 650-800-6676
Vincerx Pharma, Inc. (Filer) CIK: 0001796129 (see all company filings)

EIN.: 833197402 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39244 | Film No.: 25597330
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)